Cargando…
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
BACKGROUND: We investigated the predictive markers for the therapeutic efficacy and the best combination of sodium-glucose co-transporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and ipragliflozin) therapy in patients with type 2 diabetes mellitus (T2DM). METHODS: A total of 804 patients...
Autores principales: | Lee, Ji-Yeon, Cho, Yongin, Lee, Minyoung, Kim, You Jin, Lee, Yong-ho, Lee, Byung-Wan, Cha, Bong-Soo, Kang, Eun Seok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470102/ https://www.ncbi.nlm.nih.gov/pubmed/30688052 http://dx.doi.org/10.4093/dmj.2018.0057 |
Ejemplares similares
-
The Effectiveness of Intermittent Fasting to Reduce Body Mass Index and Glucose Metabolism: A Systematic Review and Meta-Analysis
por: Cho, Yongin, et al.
Publicado: (2019) -
Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
por: Lee, Ji-Yeon, et al.
Publicado: (2019) -
Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022) -
Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
por: Lee, Minyoung, et al.
Publicado: (2020) -
Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
por: Cho, Yongin, et al.
Publicado: (2022)